Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BridgeBio Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €-2,183.2 Mil. BridgeBio Pharma's Total Assets for the quarter that ended in Jun. 2026 was €1,056.6 Mil.
Therefore, BridgeBio Pharma's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was -2.07.
The historical rank and industry rank for BridgeBio Pharma's Equity-to-Asset or its related term are showing as below:
FRA:2CL'
s Equity-to-Asset Range Over the Past 10 Years
Min: -2.7 Med: -1.26 Max: 0.72
Current: -2.07
During the past 9 years, the highest Equity to Asset Ratio of BridgeBio Pharma was 0.72. The lowest was -2.70. And the median was -1.26.
FRA:2CL's Equity-to-Asset is ranked worse than 95.48% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs FRA:2CL: -2.07
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BridgeBio Pharma Equity-to-Asset Related Terms
BridgeBio Pharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BridgeBio Pharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2CL vs ASND, JAZZ, EXEL: Equity-to-Asset Comparison
For the Biotechnology subindustry, BridgeBio Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BridgeBio Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (FRA:2CL) has a Equity-to-Asset of -2.07 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BridgeBio Pharma and its competitors. According to the industry distribution chart, BridgeBio Pharma ranks #1351 out of 1415 companies in the Biotechnology industry, placing it in the top 95.5%.
Is BridgeBio Pharma's Equity-to-Asset too high?
BridgeBio Pharma's current Equity-to-Asset is -2.07. Based on the distribution chart, BridgeBio Pharma ranks #1351 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BridgeBio Pharma has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Equity-to-Asset compare to ASND and JAZZ?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #1351 out of 1415 companies for Equity-to-Asset. This places BridgeBio Pharma in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BridgeBio Pharma and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Pharma's current Equity-to-Asset is -2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €123.11, compared to a current price of €71.37 — trading 42% below its estimated fair value. The current Equity-to-Asset is -2.07. BridgeBio Pharma's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Equity-to-Asset is -2.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?
Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued.
The current stock price of €71.37 is trading 42% below its estimated GF Value™ of €123.11.
GuruFocus considers BridgeBio Pharma to be Possible Value Trap.
Key valuation signals for FRA:2CL:
Equity-to-Asset: -2.07
GF Value™: €123.11 vs. price of €71.37 (42% below fair value)
No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
69GF Score
Get the complete analysis for FRA:2CL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2CL has been successfully added to your 
